Serum Neopterin as a prognostic indicator in patients with gastric carcinoma

Journal of Investigative Surgery

Volumn 22, Issue 6, 2009, Pages 419-425

  Unal, B ^a   Kocer, B ^b   Altun, B ^b   Surmeli, S ^b   Aksaray, S ^b   Balci, M ^c   Ozlu, B ^b   Cengiz, O ^b  

^a INONU UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Yuksek Ihtisas Heart Education and Research Hospital   (Turkey)

Author keywords

Gastric cancer; Neopterin; Prognosis; Serum; Survival

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; NEOPTERIN;

ADULT; ARTICLE; BIOCHEMISTRY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MEDICAL RECORD; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPTERIN; PROGNOSIS; STOMACH NEOPLASMS;

EID: 72949118297     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941930903410783     Document Type: Article

References (40)

1. Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol. 1993;101:1-6.
2. Wachter H, Fuchs D, Hausen A, et al. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem. 1989;27:81-141.
3. Abate G, Comella P, Marfella A, et al. Prognostic relevance of urinary neopterin in non-Hodgkin's lymphoma. Cancer (Philadelphia). 1989;63:484-489.
4. Denz H, Griinewatd K, Thaler J, et al. Urinary neopterin as a prognostic marker in haematological neoplasias. Pteridines. 1989;1:167-170.
5. Reibnegger G, Krainer M, Herold M, et al. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res. 1991;51:6250-6253.
6. Reibnegger GJ, Bichler AH, Dapunt O, et al. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res. 1986;46:950-955.
7. Reibnegger G, Hetzel H, Fuchs D, et al. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res. 1987;47:4977-4981.
8. Prommegger R, Widner B, Murr C, et al. Neopterin: a prognostic variable in operations for lung cancer. Ann Thorac Surg. 2000;70:1861-1864.
9. Melichar B, Solichov́aD,Melicharov́aK, et al. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers. 2006;21:190-198. (Pubitemid 44660292)
10. Weiss G, Kronberger P, Conrad F, et al. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res. 1993;53:260-265.
11. Manes G, Spada OA, Rabitti PG, et al. Neopterin serum levels in pancreatic adenocarcinoma. Int J Pancreatol. 1999;25:31-37.
12. Yildirim Y, Gunel N, Coskun U, et al. Serum neopterin levels in patients with breast cancer. Med Oncol. 2008;25(4):403-407.
13. Melichar B, Solichov́a D, Svobodov́a I, et al. Urinary neopterin in patients with liver tumours. Tumouri. 2006;92:318-322. (Pubitemid 44525309)
14. Murr C, Berchtold J, Norer B, et al. Neopterin as a prognostic parameter in patientswith squamous-cell carcinomas of the oral cavity. Int J Cancer. 1998;79:476-480.
15. Melichar B, Solichov́a D, Svobodov́a I, et al. Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin. Luminescence. 2005;20:311-314.
16. Thiounn N, Pages F, Flam T, et al. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett. 1997;58:121-124.
17. Negrier S, Perol D, Menetrie-Caux C, et al. Interleukin- 6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin- 6-from the Groupe Francais d'Immunotherapie. J Clin Oncol. 2004;22:2371-2378.
18. Melichar B, Solichova D, Svobodova D, et al. Urinary neopterin in patients with upper gastrointestinal, biliary and pancreatic carcinomas. Pteridines. 2006;17:20-24.
19. Hoffmann G, Wirleitner B, Fichs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res. 2003;52:313-321.
20. Weiss G, Willeit J, Kiechl S, et al. Increased concentration of neopterin in carotid atherosclerosis. Atherosclerosis. 1994;106:263-271.
21. Kronberger P, Weiss G, Tschmelitsch J, et al. Predictive value of urinary neopterin in patients with lung cancer. Eur J Clin Chem Clin Biochem. 1995;33:831-837.
22. Kawasaki H, Watanabe H, Yamada S, et al. Prognostic significance of urinary neopterin levels in patientswith hepatocellular carcinoma. Tohoku J Exp Med. 1988;155:311-318.
23. Melichar B, Solichova D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer. 2006;16:240-252.
24. Lissoni P, Tisi E, Brivio F, et al. Increase in soluble interleukin- 2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer. 1991;27:1014-1016.
25. Aulitzky W, Gastl G, Aulitzky WE, et al. Interferon-ã for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of â-2 microglobulin and neopterin responses. Immunobiology. 1987;176:85-95.
26. Urba WJ, Kopp WC, Clark JW, et al. The in vivo immunomodulatory effects of recombinant interferon-ã plus recombinant tumour necrosis factor-á. J Clin Oncol. 1991;9:1831-1839.
27. Chiang J, Gloff CA, Yoshizawa CN, et al. Pharmacokinetics of recombinant human interferon-â in healthy volunteeras and its effect on serum neopterin. Pharm Res. 1993;10:567-572.
28. Crispino S, Lissoni P, Ardizzola A, et al. Effects of granulocyte- macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumour necrosis factor-á in cancer patients. J Biol Regul Homeost Agents. 1993;7:92-94.
29. Motzer RJ, Rakhit A, Thompson JA, et al. Randomized multicenter phase-II trial of subcutaneous recombinant human interleukin 12 vs. interferon á for patients with advanced renal cell carcinoma. J Interferon Cytokine Res. 2001;21:257-263.
30. Freedman RS, Kudelka AP, Kavanagh JJ, et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumour-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res. 2000;6:2268-2278.
31. Henderson DC, Sheldon J, Riches P, et al. Cytokine induction of neopterin production. Clin Exp Immunol. 1991;83:479-482.
32. Thiounn N, Pages F, Flam T, et al. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett. 1997;58:121-124.
33. Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27:1091-1097.
34. Wu CW, Wang SR, Chao MF, et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol. 1996;91:1417-1422.
35. Fuith LC, Daxenbichler G, Dapunt O. CA 125 in the serum and tissue of patients with gynecological disease. Arch Gynecol Obstet. 1987;241:157-164.
36. Rieder J, Jahnke R, Schloesser M, et al. Niric oxide-dependent apoptosis in ovarian carcinoma cell lines. Gynecol Oncol. 2001;82:172-176.
37. Mohamed KH, Mobaster AAMT, Yousef A-R I, et al. BAL neopterin: a novel marker for cell-mediated immunity in patients with pulmonary tuberculosis and lung cancer. Chest. 2001;119:776-780.
38. Widner B, Baier-Bitterlich G, Wede I, et al. Neopterin indicator of oxidative stres and part of the cytotoxic armature of activated macrophages in humans. Pteridines. 1998;9:91-102.
39. Hoffmann G, Frede S, Kenn S, et al. Neopterin-induced tumour necrosis factor-á synthesis in vascular smooth muscle cells in vitro. Int Arch Allergy Immunol. 1998;116:240-245.
40. Alleva DG, BurgerCJ, Elgert KD. Tumour-induced regulation of suppressormacrophage nitric oxide and TNF-alpha production. Role of tumour-derived IL-10, TGF-beta, and prostaglandin E. J Immunol. 1994;153:1674-1686.